drugset / Trial / NCT01419639
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Phase 2
Completed
10 enrolled
NYU Langone Health
Novartis Pharmaceuticals · collabThe Children's Tumor Foundation · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
Timeline
- Start
- 2011-10
- Primary completion
- 2012-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |